Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy

Quark siRNAs Examined Alone and in Combination with Chemotherapy

9/25/2008

Quark Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property

Data Validates Neuroprotective Effect of Quark’s New RNAi product on dying Retinal Ganglion Cells, a Cause of Blindness in Glaucoma

9/17/2008

Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008

7/30/2008

Quark Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in DME

Clinical Program Leverages Quark’s RNAi Technology

4/7/2008

Quark Receives FDA Approval of IND For Kidney Transplant

Quark’s second siRNA drug delivered systemically

4/7/2008

Quark Closes $27 Million Financing

Funds Will Support Clinical Development of Pipeline Products